Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.2K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.2K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

14.6K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
14.6K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

2.6K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Rab Proteins01:14

Rab Proteins

4.1K
Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
4.1K
Receptor-mediated Endocytosis01:20

Receptor-mediated Endocytosis

6.4K
Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravenous Immunoglobulin Reduces Infections for Patients with Chronic Lymphocytic Leukemia: A Single-Center Retrospective Analysis.

Cancer research communications·2026
Same author

Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

A scholar of blood and beauty: remembering Prof. Jacques-Louis Binet (1932-2024).

Leukemia·2025
Same author

Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia.

Leukemia·2025
Same author

The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers.

Science advances·2025
Same author

Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein.

Biomedicines·2024

Related Experiment Video

Updated: Sep 23, 2025

Inducible and Reversible Dominant-negative DN Protein Inhibition
08:35

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

8.5K

ROR1: an orphan becomes apparent.

Thomas J Kipps1

  • 1Center for Novel Therapeutics, Moores Cancer Center, Department of Medicine, University of California, San Diego, La Jolla, CA.

Blood
|May 17, 2022
PubMed
Summary
This summary is machine-generated.

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is crucial in development and cancer. Targeting ROR1 shows promise for treating chronic lymphocytic leukemia (CLL) and other ROR1-expressing cancers.

More Related Videos

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

13.3K
Monitoring Protein-RNA Interaction Dynamics In Vivo at High Temporal Resolution Using χCRAC
09:15

Monitoring Protein-RNA Interaction Dynamics In Vivo at High Temporal Resolution Using χCRAC

Published on: May 9, 2020

5.2K

Related Experiment Videos

Last Updated: Sep 23, 2025

Inducible and Reversible Dominant-negative DN Protein Inhibition
08:35

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

8.5K
A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

13.3K
Monitoring Protein-RNA Interaction Dynamics In Vivo at High Temporal Resolution Using χCRAC
09:15

Monitoring Protein-RNA Interaction Dynamics In Vivo at High Temporal Resolution Using χCRAC

Published on: May 9, 2020

5.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Receptor tyrosine kinase-like orphan receptor 1 (ROR1) identified in 1992 as a cell-surface receptor with unknown ligand.
  • ROR1 plays a significant role in embryonic development and various cancers.
  • Distinctive ROR1 expression in chronic lymphocytic leukemia (CLL) aids in distinguishing leukemia cells.

Purpose of the Study:

  • To review the expression and biology of ROR1.
  • To explore evolving strategies for targeting ROR1 in cancer therapy.
  • To highlight ROR1's potential in treating CLL and other ROR1-expressing malignancies.

Main Methods:

  • Literature review of studies on ROR1 expression and function.
  • Analysis of ROR1's role in the pathophysiology of CLL.
  • Evaluation of therapeutic strategies targeting ROR1.

Main Results:

  • ROR1 is significantly expressed in CLL, serving as a potential diagnostic marker.
  • ROR1 is implicated in the pathophysiology of CLL.
  • Targeting ROR1 offers therapeutic potential for CLL and other malignancies.

Conclusions:

  • ROR1 is a key molecule in CLL pathogenesis and a promising therapeutic target.
  • Targeting ROR1 may improve treatment outcomes for patients with CLL and other ROR1-expressing cancers.
  • Further research into ROR1 biology and targeting strategies is warranted.